The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04372472
Recruitment Status :
Active, not recruiting
First Posted : May 4, 2020
Last Update Posted : May 4, 2020
Biomedical Advanced Research and Development Authority
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.
To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. [ Time Frame: Day of enrollment through Day 5 ]
The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The study will enroll up to 300 participants from the emergency department at one clinical research site. Subjects who are suspected of having COVID-19 or other infectious respiratory diseases may be eligible for the study.
Subjects meeting the following criteria may be eligible for participation in the study:
≥ 18 years old or older
The first vital sign (any one of: blood pressure, temperature, pulse or respiratory rate) has been recorded in the medical record
A complete blood count has been ordered for which a blood sample has been collected within 4.5 hours since the first vital sign was recorded
Signs or suspicion of a respiratory infection, defined as:
Subject designated for evaluation in the ED respiratory or pulmonary pod or similar location. OR
An order placed for a respiratory viral panel. OR
An order placed for a SARS-CoV-2 test. OR
A subject self-reported as having tested positive for the SARS-CoV-2 test within the previous 7 days and returning with a related complaint.
Subjects are excluded from study participation if they meet any of the following criteria:
a. Blood sample volume is < 300 ul; insufficient quantity for SeptiScan testing.